Elicio Therapeutics, Inc.
NCM: ELTXLive Quote
About Elicio Therapeutics, Inc.
Healthcare
Biotechnology
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
📊 Fundamental Analysis
Elicio Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
At a current price of $10.15, ELTX currently sits at the 54th percentile of its 52-week range (Range: $4.61 - $14.93).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$271.02M
Trailing P/E
--
Forward P/E
-7.25
Beta (5Y)
1.88
52W High
$14.93
52W Low
$4.61
Avg Volume
135K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App